Welcome!

News Feed Item

North America In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

NEW YORK, Dec. 17, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

North America In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
http://www.reportlinker.com/p0763031/North-America-In-Vitro-Diagnostics-Market-Outlook-to-2018--Clinical-Chemistry-Genetic-Testing-Haematology-Histology-and-Cytology-Immuno-Chemistry-Infectious-Immunology-and-Microbiology-Culture.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

North America In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Summary

GlobalData's new report, "North America In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture" provides key market data on the North America In Vitro Diagnostics market – Canada and United States. The report provides value (USD million) data for all the market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

- Countries covered include Canada and United States.
- Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
- Annualized market revenues (USD million) data for each of the market categories in each of the country. Data from 2004 to 2011, forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the market categories and countries.
- Global corporate-level profiles of key companies operating within the North America In Vitro Diagnostics market..
- Key players covered include Siemens Healthcare, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., Alere Inc. and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the North America In Vitro Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what's the most preferred mode of product distribution – Identify, understand and capitalize.

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 15
2 Introduction 16
2.1 What is This Report About? 16
3 In Vitro Diagnostics in North America 17
3.1 In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, 2004-2018 17
3.2 In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, 2004-2018 18
3.3 In Vitro Diagnostics, North America, Company share (2010-2011) 26
4 In Vitro Diagnostics In United States 28
4.1 In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, 2004-2018 28
4.2 In Vitro Diagnostics, United States, Distribution Share (2010-2011) 34
4.3 In Vitro Diagnostics, United States, Company Share (2010-2011) 38
5 In Vitro Diagnostics In Canada 51
5.1 In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, 2004-2018 51
5.2 In Vitro Diagnostics, Canada, Distribution Share (2010-2011) 57
5.3 Clinical Chemistry Distribution Share (2010-2011) 57
5.4 In Vitro Diagnostics, Canada, Company Share (2010-2011) 61
5.5 Microbiology Culture, Canada, Company Share (2010-2011) 75
6 Overview of Key Companies in North America In Vitro Diagnostics 77
6.1 Siemens Healthcare 77
6.2 Abbott Laboratories 78
6.3 F. Hoffmann-La Roche Ltd. 79
6.4 Beckman Coulter, Inc. 80
6.5 Ortho-Clinical Diagnostics Inc. 81
6.6 Alere Inc. 82
6.7 bioMerieux S.A. 83
6.8 Becton, Dickinson and Company 83
6.9 Bio-Rad Laboratories, Inc. 84
6.10 Sysmex Corporation 84
6.11 Qiagen N.V. 85
6.12 Gen-Probe Incorporated 85
6.13 DiaSorin S.p.A 86
6.14 Immucor, Inc. 86
6.15 Thermo Fisher Scientific Inc. 87
6.16 Hologic, Inc. 87
6.17 Cepheid 88
6.18 PerkinElmer, Inc. 88
6.19 Grifols, S.A. 89
6.20 ELITech Group 89
6.21 Life Technologies Corporation 90
6.22 Horiba, Ltd. 90
6.23 Biomedica Diagnostics Inc. 91
6.24 Diagnostica Stago, Inc. 91
6.25 OraSure Technologies, Inc. 91
7 North America Market Pipeline Products 92
7.1 Clinical Chemisty Market Pipeline Products 92
7.2 Immuno Chemistry Market Pipeline Products 99
7.3 Haematology Market Pipeline Products 110
7.4 Infectious Immunology Market Pipeline Products 112
7.5 Microbiology Culture Market Pipeline Products 119
7.6 Histology And Cytology Market Pipeline Products 121
7.7 Genetic Testing Market Pipeline Products 122
8 Financial Deals Landscape 127
8.1 Acquisition 127
8.2 Partnerships 177
9 Recent Developments 442
9.1 Strategy And Business Planning 442
9.2 Research And Development 474
9.3 Legal and Regulatory 482
9.4 Government and Public Interest 511
9.5 Product News 572
10 Appendix 734
10.1 Definitions of Markets Covered in the Report 735
10.2 Research Methodology 746
10.3 Secondary Research 746
10.4 Primary Research 747
10.5 Models 747
10.6 Forecasts 748
10.7 Expert Panels 748
10.8 GlobalData Consulting 748
10.9 Currency Conversion 749
10.10 Contact Us 749
10.11 Disclaimer 749

List of Tables

Table 1: In Vitro Diagnostics, Cross Country Comparison, Revenue ($m),USD Constant, 2004-2018 44
Table 2: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, 2004-2018 46
Table 3: In Vitro Diagnostics, North America, Cross-Category Analysis, 2004-2018 48
Table 4: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, Historic, 2004-2011 50
Table 5: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 52
Table 6: In Vitro Diagnostics, North America, Company share by Revenue ($m), USD Constant, 2010-2011 54
Table 7: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, 2004-2018 56
Table 8: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Historic, 2004-2011 58
Table 9: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 60
Table 10: Clinical Chemistry, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 61
Table 11: Genetic Testing, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 61
Table 12: Haematology, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 62
Table 13: Histology And Cytology, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 62
Table 14: Immuno Chemistry, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 63
Table 15: Infectious Immunology, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 63
Table 16: Microbiology Culture, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 64
Table 17: In Vitro Diagnostics, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 66
Table 18: Clinical Chemistry, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 67
Table 19: Genetic Testing, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 69
Table 20: Haematology, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 71
Table 21: Immuno Chemistry, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 73
Table 22: Infectious Immunology, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 75
Table 23: Microbiology Culture, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 77
Table 24: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, 2004-2018 79
Table 25: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, Historic, 2004-2011 81
Table 26: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 83
Table 27: Clinical Chemistry, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011 84
Table 28: Genetic Testing, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011 84
Table 29: Haematology, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011 85
Table 30: Histology And Cytology, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011 85
Table 31: Immuno Chemistry, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011 86
Table 32: Infectious Immunology, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011 86
Table 33: Microbiology Culture, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011 87
Table 34: In Vitro Diagnostics, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011 89
Table 35: Clinical Chemistry, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011 91
Table 36: Genetic Testing, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011 93
Table 37: Haematology, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011 95
Table 38: Histology And Cytology, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011 97
Table 39: Immuno Chemistry, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011 99
Table 40: Infectious Immunology, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011 101
Table 41: Microbiology Culture, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011 103
Table 42: Clinical Chemisty Market Pipeline Products 119
Table 43: Immuno Chemistry Market Pipeline Products 126
Table 44: Haematology Market Pipeline Products 137
Table 45: Infectious Immunology Market Pipeline Products 139
Table 46: Microbiology Culture Market Pipeline Products 146
Table 47: Histology And Cytology Market Pipeline Products 148
Table 48: Genetic Testing Market Pipeline Products 149
Table 49: SQI Diagnostics Plans For Sale Of The Company 154
Table 50: Sparton Completes Acquisition Of Onyx EMS, Contract Manufacturing Services Provider, For $43 Million 155
Table 51: ERBA Diagnostics Acquires Drew Scientific, Maker Of Analytical Instruments And Reagents, For $6.5 Million 157
Table 52: Measurement Specialties Acquires Cambridge Technologies And Resistance Temperature Detector Company For $18.8 Million 159
Table 53: Atossa Genetics Acquires Acueity Healthcare, Diagnostic Device Provider 160
Table 54: AccelPath Acquires DigiPath Solutions For $2.4 Million 161
Table 55: Danaher Completes Acquisition Of 91.6% Stake In Iris International, Diagnostic Test Maker, For $324 Million 162
Table 56: Charles River Labs Acquires Accugenix, Provider Of Microbe Identification Services, For $17 Million 164
Table 57: Leica Biosystems Completes Acquisition Of Aperio Technologies 166
Table 58: Metabolon Acquires Lipomics Technologies, Diagnostics Company 169
Table 59: Waters Acquires Blue Reference, Maker Of Application Scientific Databases, For $14 Million 171
Table 60: Life Technologies Acquires Pinpoint Genomics, Molecular Diagnostics Company 172
Table 61: Thermo Fisher Scientific Completes Acquisition Of One Lambda, Transplant Diagnostics Company, For $925 Million 173
Table 62: Life Technologies Acquires Navigenics 175
Table 63: Genova Diagnostics Acquires Metametrix, Clinical Laboratory 177
Table 64: 23andMe Acquires CureTogether, Healthcare IT Company 178
Table 65: Luminex To Acquire GenturaDx, Molecular Diagnostics Company, For $50 Million 179
Table 66: Systagenix Acquires O2 Insights 181
Table 67: Maxxam Analytics Acquires Becquerel Labs, Provider Of Testing Services 182
Table 68: LabCorp Completes Acquisition Of Medtox Scientific For $241 Million 183
Table 69: Flagship Biosciences Acquires Ihctech, Provider Of Research Immunohistochemistry And Histology Services 185
Table 70: Halo Healthcare Acquires NeoMatrix, Maker Of Diagnostic Equipments 186
Table 71: Pacepartners To Acquire Vivione BioSciences 187
Table 72: Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 188
Table 73: Hologic Completes Acquisition Of Gen-Probe For $3.7 Billion 189
Table 74: Haemonetics To Acquire Hemerus Medical, Provider Of Leukoreduction Technologies, For $27 Million 192
Table 75: IntegenX Acquires SV, Provider Of DNA Identification Consumable Products, From GE Healthcare Bio-Sciences 194
Table 76: Beckman Coulter Acquires Blue Ocean Biomedical From Npe Systems 195
Table 77: Abcam Completes Acquisition Of Epitomics, Rabbit Monoclonal Antibodies Provider, For $155 Million 196
Table 78: Ontario Genomics Institute Acquires Minority Stake In RNA Diagnostics For $0.1 Million 198
Table 79: PhotoVoltaic Solar Cells Acquires MetaStat, Life Science Company 199
Table 80: Alere To Acquire eScreen, Provider Of Health Testing Products And Services, For Up To $340 Million 200
Table 81: Bode Technology Group Acquires Provider Of DNA Analysis Testing Services, Chromosomal Labs 202
Table 82: Signal Genetics To Acquire Molecular Diagnostics Company, ChipDX 203
Table 83: Multiple Myeloma Research Foundation Enters Into Co-Development Agreement With GenoSpace 204
Table 84: Empire Genomics Enters Into Licensing Agreement With Emory University For Genomic Biomarkers 205
Table 85: NanoPass Technologies Enters Into Licensing Agreement With Janssen Pharma For MicronJet 206
Table 86: Cisbio Bioassays Enters Into Distribution Agreement With BellBrook Labs For Transcreener Epigen Methyltransferase Assay 207
Table 87: BioView Enters Into Agreement With Abbott To Develop Automated Cancer Screening System 209
Table 88: Institute of Microelectronics Enters Into Co-Development Agreement With SFC Fluidics 210
Table 89: HTG Molecular Diagnostics Enters Into Licensing Agreement With Centre of Excellence for Prevention of Organ Failure For COPD Prognostic Test 211
Table 90: Pressure BioSciences Enters Into Co-Marketing Agreement With Constant Systems For High Pressure Technologies 212
Table 91: CML HealthCare Enters Into Licensing Agreement With Mitomics For Prostate Cancer Test 214
Table 92: bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 215
Table 93: DioGenix Enters Into Agreement With Fast Forward To Develop New Blood Test For Multiple Sclerosis 217
Table 94: GNS Healthcare Enters Into Agreement With Dana-Farber Cancer Institute and Mount Sinai School of Medicine 219
Table 95: Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 221
Table 96: CombiMatrix Enters Into Co-Marketing Agreement With Pathology For Prenatal Tests 222
Table 97: Clinical Genomics Enters Into Licensing Agreement With Quest Diagnostics For Colon Cancer Markers 223
Table 98: Abaxis Enters Into Distribution Agreement With Abbott Point of Care For Piccolo Blood Chemistry System 224
Table 99: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For Archimedes Particle Metrology System 226
Table 100: Malvern Instruments Enters Into Co-Marketing Agreement With Affinity Biosensors For Archimedes Particle Metrology System 227
Table 101: Exosome Diagnostics Enters Into Co-Development Agreement With Promega For Urine Clinical Sample Concentrator Kit 228
Table 102: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 229
Table 103: Ezose Enters Into Co-Development Agreement With Fast Forward For Multiple Sclerosis Biomarkers 230
Table 104: BioDot Enters Into Co-Marketing Agreement With JOT Automation 231
Table 105: Sequella Enters Into Licensing Agreement With LabCorp For B-Smart Technology 232
Table 106: LifeTech Scientific, DiNova Venture Partners, Themes Investment Partners And Broncus Technologies Partner To Form Broncus Medical 233
Table 107: Van Andel Institute Enters Into Co-Development Agreement With Emory University 235
Table 108: Merck Serono Enters Into Co-Development Agreement With Auxogyn For Early Embryo Viability Assessment Test 236
Table 109: PGXL Labs Enters Into Joint Venture Agreement With Essential Molecular Testing 237
Table 110: Broad Institute Enters Into Distribution Agreement With Appistry For Genome Analysis Toolkit 238
Table 111: Thermo Fisher Enters Into Co-Development Agreement With Immundiagnostik 239
Table 112: Sage Labs Enters Into Agreement With Ekam Imaging To Develop Imaging Assays 240
Table 113: Bruker Enters Into An Agreement With Nextval For High-throughput Screening Technology 241
Table 114: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays 242
Table 115: RainDance Technologies Enters Into Co-Development Agreement With Integrated DNA Technologies For Digital PCR 243
Table 116: Amarantus BioSciences Enters Into Option For Licensing Agreement With Memory Dx For LymPro Blood Test 245
Table 117: Iverson Genetic Diagnostics Enters Into Licensing Agreement With Johns Hopkins University School For Molecular Diagnostic Tests 246
Table 118: Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 247
Table 119: Mitomics Enters Into Co-Marketing Agreement With LabCorp For Prostate Core Mitomic Test 248
Table 120: Trillium Diagnostics Enters Into Licensing Agreement With Leukocare For Sepsis Dx 250
Table 121: Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 251
Table 122: Vela Diagnostics Enters Into Licensing Agreement With Life Technologies 252
Table 123: Augurex Life Sciences Enters Into Licensing Agreement With Quest Diagnostics For 14-3-3n Biomarker 253
Table 124: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital Microscopy Hematology Solutions 254
Table 125: Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 256
Table 126: Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress Dx Test 258
Table 127: Genia Technologies Enters Into Co-Development Agreement With Columbia University And Harvard University 260
Table 128: NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers 262
Table 129: Proof Centre Enters Into Co-Development Agreement With AllerGen For Allergy Biomarkers 263
Table 130: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology 264
Table 131: Atossa Enters Into Co-Marketing Agreement With Diagnostics Test Group For MASCT System 265
Table 132: Genalyte Partners Scienion To Provide Sciflexarrayer Dispensers For Maverick Detection Platform 266
Table 133: CML HealthCare Enters Into Agreement With MaRS Innovation 267
Table 134: Life Technologies Enters Into Agreement With Bristol-Myers Squibb For Companion Diagnostics Development 268
Table 135: Agilent Technologies Enters Into Co-Marketing Agreement With Molecular Discovery 269
Table 136: Agilent Technologies Enters Into Co-Marketing Agreement With MRM Proteomics 270
Table 137: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women's Hospital For Mesothelioma Test 271
Table 138: Illumina Enters Into Technology Integration Agreement With Partners HealthCare System 272
Table 139: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein Array Products 274
Table 140: ImaginAb Enters Into Co-Development Agreement With MacroGenics 275
Table 141: BellBrook Labs Enters Into Co-Development Agreement With Reaction Biology 276
Table 142: GVK Biosciences Enters Into Licensing Agreement With National Cancer Institute For GOBIOM Database 277
Table 143: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North Carolina 278
Table 144: Perkinelmer Enters Into Co-Development Agreement With Massachusetts General Hospital 279
Table 145: Affymetrix Enters Into Co-Development Agreement With Pathgen Dx 281
Table 146: Axela Enters Into Co-Marketing Agreement With OvaGene Oncology 282
Table 147: University of Michigan Enters Into Joint Venture Agreement With International Genomics Consortium 283
Table 148: Regulus Therapeutics Enters Into An Agreement With Biogen Idec For Biomarkers 284
Table 149: Curetis Enters Into Licensing Agreement With Cempra For Unyvero 285
Table 150: Foundation Medicine Enters Into Co-Development Agreement With Clovis Oncology 286

List of Figures

Figure 1: In Vitro Diagnostics, Cross Country Comparison, Revenue ($m), USD Constant, 2004-2018 44
Figure 2: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, 2004-2018 45
Figure 3: In Vitro Diagnostics, North America, Cross-Category Analysis, 2004-2018 47
Figure 4: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, Historic, 2004-2011 49
Figure 5: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 51
Figure 6: In Vitro Diagnostics, North America, Company share (%), 2011 53
Figure 7: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, 2004-2018 55
Figure 8: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Historic, 2004-2011 57
Figure 9: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 59
Figure 10: In Vitro Diagnostics, United States, Company Share (%), 2011 65
Figure 11: Clinical Chemistry, United States, Company Share (%), 2011 67
Figure 12: Genetic Testing, United States, Company Share (%), 2011 68
Figure 13: Haematology, United States, Company Share (%), 2011 70
Figure 14: Immuno Chemistry, United States, Company Share (%), 2011 72
Figure 15: Infectious Immunology, United States, Company Share (%), 2011 74
Figure 16: Microbiology Culture, United States, Company Share (%), 2011 76
Figure 17: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, 2004-2018 78
Figure 18: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, Historic, 2004-2011 80
Figure 19: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 82
Figure 20: In Vitro Diagnostics, Canada, Company Share (%), 2011 88
Figure 21: Clinical Chemistry, Canada, Company Share (%), 2011 90
Figure 22: Genetic Testing, Canada, Company Share (%), 2011 92
Figure 23: Haematology, Canada, Company Share (%), 2011 94
Figure 24: Histology And Cytology, Canada, Company Share (%), 2011 96
Figure 25: Immuno Chemistry, Canada, Company Share (%), 2011 98
Figure 26: Infectious Immunology, Canada, Company Share (%), 2011 100
Figure 27: Microbiology Culture, Canada, Company Share (%), 2011 102
Figure 28: Siemens Healthcare, Company Share (%), North America In Vitro Diagnostics Market, 2011 104
Figure 29: Abbott Laboratories, Company Share (%),North America In Vitro Diagnostics Market, 2011 105
Figure 30: F. Hoffmann-La Roche Ltd., Company Share (%),North America In Vitro Diagnostics Market, 2011 106
Figure 31: F. Hoffmann-La Roche Ltd., Company Share (%),North America In Vitro Diagnostics Market, 2011 107
Figure 32: Ortho-Clinical Diagnostics Inc., Company Share (%),North America In Vitro Diagnostics Market, 2011 108
Figure 33: Alere Inc, Company Share (%),North America In Vitro Diagnostics Market, 2011 109

Companies mentioned
Siemens Healthcare
Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Beckman Coulter, Inc.
Ortho-Clinical Diagnostics Inc.
Alere Inc.
bioMerieux S.A.
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Sysmex Corporation
Qiagen N.V.
Gen-Probe Incorporate


To order this report:
In_Vitro_Diagnostic Industry:
North America In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

__________________________
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Technology vendors and analysts are eager to paint a rosy picture of how wonderful IoT is and why your deployment will be great with the use of their products and services. While it is easy to showcase successful IoT solutions, identifying IoT systems that missed the mark or failed can often provide more in the way of key lessons learned. In his session at @ThingsExpo, Peter Vanderminden, Principal Industry Analyst for IoT & Digital Supply Chain to Flatiron Strategies, will focus on how IoT depl...
Data is an unusual currency; it is not restricted by the same transactional limitations as money or people. In fact, the more that you leverage your data across multiple business use cases, the more valuable it becomes to the organization. And the same can be said about the organization’s analytics. In his session at 19th Cloud Expo, Bill Schmarzo, CTO for the Big Data Practice at Dell EMC, introduced a methodology for capturing, enriching and sharing data (and analytics) across the organization...
With all the incredible momentum behind the Internet of Things (IoT) industry, it is easy to forget that not a single CEO wakes up and wonders if “my IoT is broken.” What they wonder is if they are making the right decisions to do all they can to increase revenue, decrease costs, and improve customer experience – effectively the same challenges they have always had in growing their business. The exciting thing about the IoT industry is now these decisions can be better, faster, and smarter. Now ...
WebRTC is about the data channel as much as about video and audio conferencing. However, basically all commercial WebRTC applications have been built with a focus on audio and video. The handling of “data” has been limited to text chat and file download – all other data sharing seems to end with screensharing. What is holding back a more intensive use of peer-to-peer data? In her session at @ThingsExpo, Dr Silvia Pfeiffer, WebRTC Applications Team Lead at National ICT Australia, looked at differ...
"Splunk basically takes machine data and we make it usable, valuable and accessible for everyone. The way that plays in DevOps is - we need to make data-driven decisions to delivering applications," explained Andi Mann, Chief Technology Advocate at Splunk and @DevOpsSummit Conference Chair, in this SYS-CON.tv interview at @DevOpsSummit at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
The cloud market growth today is largely in public clouds. While there is a lot of spend in IT departments in virtualization, these aren’t yet translating into a true “cloud” experience within the enterprise. What is stopping the growth of the “private cloud” market? In his general session at 18th Cloud Expo, Nara Rajagopalan, CEO of Accelerite, explored the challenges in deploying, managing, and getting adoption for a private cloud within an enterprise. What are the key differences between wh...
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
"Logz.io is a log analytics platform. We offer the ELK stack, which is the most common log analytics platform in the world. We offer it as a cloud service," explained Tomer Levy, co-founder and CEO of Logz.io, in this SYS-CON.tv interview at DevOps Summit, held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA.
In his session at @DevOpsSummit at 19th Cloud Expo, Robert Doyle, lead architect at eCube Systems, will examine the issues and need for an agile infrastructure and show the advantages of capturing developer knowledge in an exportable file for migration into production. He will introduce the use of NXTmonitor, a next-generation DevOps tool that captures application environments, dependencies and start/stop procedures in a portable configuration file with an easy-to-use GUI. In addition to captur...
"ReadyTalk is an audio and web video conferencing provider. We've really come to embrace WebRTC as the platform for our future of technology," explained Dan Cunningham, CTO of ReadyTalk, in this SYS-CON.tv interview at WebRTC Summit at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Due of the rise of Hadoop, many enterprises are now deploying their first small clusters of 10 to 20 servers. At this small scale, the complexity of operating the cluster looks and feels like general data center servers. It is not until the clusters scale, as they inevitably do, when the pain caused by the exponential complexity becomes apparent. We've seen this problem occur time and time again. In his session at Big Data Expo, Greg Bruno, Vice President of Engineering and co-founder of StackIQ...
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and Containers together help companies to achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of D...
In 2014, Amazon announced a new form of compute called Lambda. We didn't know it at the time, but this represented a fundamental shift in what we expect from cloud computing. Now, all of the major cloud computing vendors want to take part in this disruptive technology. In his session at 20th Cloud Expo, John Jelinek IV, a web developer at Linux Academy, will discuss why major players like AWS, Microsoft Azure, IBM Bluemix, and Google Cloud Platform are all trying to sidestep VMs and containers...
The many IoT deployments around the world are busy integrating smart devices and sensors into their enterprise IT infrastructures. Yet all of this technology – and there are an amazing number of choices – is of no use without the software to gather, communicate, and analyze the new data flows. Without software, there is no IT. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, Dave McCarthy, Director of Products at Bsquare Corporation; Alan Williamson, Principal ...